Search

Your search keyword '"Blum, Mariela A."' showing total 202 results
Start Over Author "Blum, Mariela A." Publication Type Academic Journals
202 results on '"Blum, Mariela A."'

1. Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.

Author

Badgwell, Brian, Ikoma, Naruhiko, Blum, Mariela, Wang, Xuemei, Estrella, Jeannelyn, Liu, Xiaoqian, Kawedia, Jitesh, Li, Jenny, Mansfield, Paul, and Ajani, Jaffer

Abstract

Background: The purpose of this phase 1 trial was to evaluate the safety and toxicity of repeated normothermic intraperitoneal paclitaxel (PTX) for patients with gastric cancer metastatic to the peritoneum. Methods: A Bayesian optimal interval design was used to prospectively identify the safety and tolerability of escalating doses of intraperitoneal paclitaxel at weekly treatments for 3 weeks, followed by a 1‐week break, and then three additional treatments. The primary objective was to define the maximum tolerated dose. Secondary end points included safety, tolerability, and antitumor activity. Results: A total of 25 patients were treated between January 2020 and April 2023. Five dose‐limiting toxicities were observed at 100 mg/m2. Treatment‐related grade 3–4 toxicity included leukopenia (32%) and neutropenia (32%). Seven patients required a schedule change to every other week treatments. The maximum tolerated dose for intraperitoneal PTX was 100 mg/m2. The peritoneum post‐intraperitoneal PTX demonstrated progression in five (20%), stable disease in five (20%), improvement in 10 (40%), and not evaluable in five (20%). Eight patients (32%) had resolution of their peritoneal disease and seven (28%) underwent attempted resection. The median overall survival (OS) from the diagnosis of metastatic disease was 18.8 months and from the date of treatment initiation was 10.8 months. One‐, 2‐, and 3‐year OS rates from the diagnosis of metastatic disease were 84%, 38%, and 25%, respectively. Conclusions: Paclitaxel may be safely used at intraperitoneal doses of 100 mg/m2. Neutropenia associated with weekly treatments was common. Peritoneal complete clinical response rates with multimodality therapy including PTX were promising. This phase 1 trial evaluated the safety, toxicity, and preliminary antitumor activity of intraperitoneal paclitaxel for patients with gastric cancer metastatic to the peritoneum. Paclitaxel may be safely used at intraperitoneal doses of 100 mg/m2. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

20. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial

Author

Welsh, James W., Seyedin, Steven N., Allen, Pamela K., Hofstetter, Wayne L., Ajani, Jaffer A., Chang, Joe Y., Gomez, Daniel R., Amini, Arya, Swisher, Stephen G., Blum, Mariela A., Younes, Ahmed I., Nguyen, Quynh-Nhu, Minsky, Bruce D., Erasmus, Jeremy J., Lee, Jeffrey H., Bhutani, Manoop, and Komaki, Ritsuko U.

Published
2017
Full Text
View/download PDF

22. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients

Author

Elimova, Elena, Wang, Xuemei, Etchebehere, Elba, Shiozaki, Hironori, Shimodaira, Yusuke, Wadhwa, Roopma, Planjery, Venkatram, Charalampakis, Nikolaos, Blum, Mariela A., Hofstetter, Wayne, Lee, Jeff H., Weston, Brian R., Bhutani, Manoop S., Rogers, Jane E., Maru, Dipen, Skinner, Heath D., Macapinlac, Homer A., and Ajani, Jaffer A.

Published
2015
Full Text
View/download PDF

24. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial

Author

Shimodaira, Yusuke, Slack, Rebecca S, Harada, Kazuto, Chen, Hsiang-Chun, Sagebiel, Tara, Bhutani, Manoop S, Lee, Jeffrey H, Weston, Brian, Elimova, Elena, Lin, Quan, Amlashi, Fatemeh G, Mizrak Kaya, Dilsa, Blum, Mariela A, Roth, Jack A, Swisher, Stephen G, Skinner, Heath D, Hofstetter, Wayne L, Rogers, Jane E, Mares, Jaennette, Thomas, Irene, Maru, Dipen M, Komaki, Ritsuko, Walsh, Garrett, and Ajani, Jaffer A

Published
2018
Full Text
View/download PDF

42. Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy.

Author

Abu‐Sbeih, Hamzah, Szafron, David, Elkafrawy, Ahmed A., Garcia‐Rodriguez, Victor, Ma, Weijie, Xu, Ann, Khurana, Shruti, Numan, Laith, Chen, Ellie, Goldstein, Ryan, Tsen, Adrianne, Peng, Yuanzun, Blum, Mariela, Kopetz, Edmund S, Ikoma, Naruhiko, Shatila, Malek, Qiao, Wei, Raju, Gottumukkala S., Ross, William A, and Ge, Phillip S

Subjects
GASTROINTESTINAL hemorrhage, ENDOSCOPY, DIAGNOSIS, HEMOSTASIS, THERAPEUTICS, ENDOSCOPIC hemostasis
Abstract

Background and Aim: The diagnosis and treatment of gastrointestinal (GI) bleeding secondary to malignancy can be challenging. Endoscopy is the gold standard to diagnose and treat gastrointestinal bleeding but clinical characteristics and outcomes of patients with malignancy‐related bleeding are not well understood. This study aims to look at clinical characteristics, endoscopic findings, safety and clinical outcomes of endoscopic interventions for GI malignancy‐related bleeding. Methods: We retrospectively reviewed outcomes of patients with confirmed GI malignancies who underwent endoscopy for GI bleeding at MD Anderson Cancer Center between 2010 and 2019. Cox hazard analysis was conducted to identify factors associated with survival. Results: A total of 313 patients were included, with median age of 59 years; 74.8% were male. The stomach (30.0%) was the most common tumor location. Active bleeding was evident endoscopically in 47.3% of patients. Most patients (77.3%) did not receive endoscopic treatment. Of the patients who received endoscopic treatment, 57.7% had hemostasis. No endoscopy‐related adverse events were recorded. Endoscopic treatment was associated with hemostasis (P < 0.001), but not decreased recurrent bleeding or mortality. Absence of active bleeding on endoscopy, stable hemodynamic status at presentation, lower cancer stage, and surgical intervention were associated with improved survival. Conclusions: This study indicates that endoscopy is a safe diagnostic tool in this patient population; while endoscopic treatments may help achieve hemostasis, it may not decrease the risk of recurrent bleeding or improve survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results